Akebia Therapeutics, Inc. AKBA 深 滬
已收盤 05-08 16:00:00 美东时间
1.16
-0.020
-1.69%
華盛通- 最 高1.20
- 今 開1.17
- 成交量 439.80万股
- 最 低 1.125
- 昨 收 1.18
- 總市值 3.11亿
- 52周最高 4.0787
- 市盈率 靜 --
- 換手率 1.64%
- 52周最低 1.125
- 委 比 -65.94%
- 總股本 2.68亿
- 歷史最高 31.00
- 量 比 0.92
- 振 幅 6.36%
- 歷史最低 0.241
- 每 手 1
- 風險率 0.93%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Akebia Therapeutics Balances Vafseo Momentum With Headwinds
Akebia Therapeutics (($AKBA)) has held its Q1 earnings call. Read on for the ma...
05-09 09:21
Akebia Therapeutics Announces Publication Of Post-Hoc Win Statistics Analysis Of All-Cause Mortality And Hospitalization From Its Global Phase 3 INNO2VATE Program In The Journal Of The American Society Of Nephrology
"The win statistics analysis highlighted favorable outcomes and potential clinical differentiation for Vafseo that we believe are central to ensure informed clinical decision-making for nephrologists and other care
05-04 20:10
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics granted stock options to 7 new employees totaling 208,800 shares on April 30, 2026, as an inducement for employment. The options, priced at $1.38 per share (the closing price on the grant date), vest over four years with 25% after the first year and the remaining 75% quarterly thereafter, contingent on continued employment. Each option has a 10-year term and is subject to Akebia’s inducement award program and stock option agre...
05-04 20:05
Akebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090
Akebia Therapeutics announced the initiation of a Phase 1 clinical trial for AKB-9090, a HIF-PH inhibitor being evaluated for cardiac surgery-associated acute kidney injury (AKI). The randomized, double-blind, placebo-controlled study aims to assess safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy adults. AKB-9090 is internally developed and considered a promising candidate for treating AKI, with top-line data expected in e...
04-13 12:00
美股大行评级 | 高盛首予PayPay“买入”评级；神经分泌生物科学获花旗等多家机构上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Enlivex"买入"评级，目标价从13美元升至20美元；韦德布什：维持FuboTV"跑赢大市"评级，目标价从3.5美元升至24美元
04-08 18:35
BTIG Reiterates Buy on Akebia Therapeutics, Maintains $4 Price Target
BTIG analyst Julian Harrison reiterates Akebia Therapeutics (NASDAQ:AKBA) with a Buy and maintains $4 price target.
04-07 18:05
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
On March 31, 2026, Akebia Therapeutics granted 13 new employees options to purchase 679,900 shares of its common stock. The options were granted as inducement material for employment and comply with Nasdaq Listing Rule 5635(c)(4). The exercise price is $1.39 per share, equal to the stock's closing price on the grant date. The options vest over four years, with 25% vesting on the first anniversary and the remaining 75% vesting quarterly thereafter...
04-02 20:05
Akebia Therapeutics Appoints Biopharmaceutical Leader Philip Vickers, Ph.D. to its Board of Directors
Akebia Therapeutics announced the appointment of Philip J. Vickers, a biopharmaceutical leader, to its Board of Directors, effective April 1, 2026. Dr. Vickers brings over three decades of experience in drug development and leadership across various biopharmaceutical companies. His expertise is expected to support Akebia's advancements in kidney and rare diseases. Additionally, Steven C. Gilman, Ph.D., retired from the Board of Directors on the s...
04-01 20:05
Akebia Therapeutics to Host Virtual R&D Day Highlighting Robust Kidney Disease Pipeline, on April 2, 2026
Akebia Therapeutics announced a virtual R&D Day on April 2, 2026, featuring experts discussing its kidney disease pipeline: Praliciguat (Phase 2 for FSGS), AKB-097 (Phase 2 basket trial for rare kidney diseases), and AKB-9090 (Phase 1 for AKI). Registration and details available via the provided link.
03-19 20:05
Q32 Bio Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update
-- Completed enrollment in Part B of SIGNAL-AA Phase 2a clinical trial and increased trial size to 33 patients based on patient demand; 36-week topline data readout expected in mid-2026 -- -...
03-10 18:59
